Prothena Public Limited's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Prothena Public Limited (PRTA) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Prothena Public Limited vs Its Competitors
- TTM: Trailing 12-month revenue of 55M vs 352,750M combined for its competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-92.6% annualized vs trailing 12 months), vs accelerating (+4.6%) for its tracked peer group.
- Growth: Prothena Public Limited generated -77.2% revenue growth year over year in Q2 2026, vs 17.6% for its competitors combined.
- Profitability: Its -1,839.9% net margin compares with 19.1% for the peer group.
- Scale: Prothena Public Limited ranks #197 of 545 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.0% of industry market cap.
- Peer revenue share: Prothena Public Limited accounted for 0.0% of combined revenue among its tracked peer group, down from 0.0% a year earlier.
- Peer differentiation: Revenue per employee of $0.81M compares with $1.22M for the peer group (0.7x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
PRTA Sales vs. its Competitors, Q2 2026
Prothena Public Limited reported revenue contraction of 77.15 % year on year in Q2 2026, below its competitors' combined revenue growth of 17.57 %.
With a net margin of -1,839.90 %, Prothena Public Limited reported lower profitability than its competitors (19.06 %).
Prothena Public Limited generated 0.00 % of the combined sales of its peer group, down from 0.01 % a year earlier.
API endpoints for this dataset
Prothena Public Limited vs. its Competitors, Q2 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Prothena Public Limited reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Prothena Public Limited and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Prothena Corporation Public Limited Company | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (3) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (8) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Prothena Public Limited's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 8.9% year over year, combined, vs -77.2% for Prothena Public Limited. Prothena Public Limited's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Prothena Public Limited's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Prothena Corporation Public Limited Company | No | Yes | Yes | No |
| Competitors combined (86) | ||||
| High-Confidence Competitors (4) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
PRTA Stock Performance relative to its Competitors
PRTA Stock Performance relative to High-Confidence Competitors
PRTA Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Ventyx Biosciences Inc | 282.9% | Outperformed |
| 2 | Damora Therapeutics Inc | 282.9% | Outperformed |
| 3 | Regulus Therapeutics Inc | 282.9% | Outperformed |
| 4 | Silence Therapeutics Plc | 282.9% | Outperformed |
| 5 | Prelude Therapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Prothena Public Limited's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Prothena Public Limited's Comment on Competition and Industry Peers
Publicly Traded Peers of Prothena Corporation Public Limited Company
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Prothena Corporation Public Limited Company |
457.57 | 54.53 |
 Eli Lilly And Company |
1,261,319.90 | 86,462.00 |
 Beone Medicines Ltd |
628,232.68 | 6,128.24 |
 Abbvie Inc |
519,727.60 | 66,014.00 |
 Astrazeneca Plc |
295,827.18 | 58,739.00 |
 Amgen Inc |
253,085.12 | 38,095.00 |
| SUBTOTAL | 3,690,933.40 | 463,601.00 |
Sign in to see all competitors of Prothena Corporation Public Limited Company.
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Prothena Corporation Public Limited Company versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Prothena Public Limited's Competitors Named by the Company
Competitive relationships identified from Prothena Public Limited reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Boehringer Ingelheim Biopharmaceuticals GmbH | Company report | 85% |
| Neumora Therapeutics Inc | Company report | 85% |
| Voyager Therapeutics Inc | Company report | 85% |
| Elan | Company report | 85% |
| Neurosense Therapeutics Ltd | Company report | 85% |
| Perrigo Company plc | Company report | 85% |
| Bristol myers Squibb Company | Company report | 85% |
| Neurocrine Biosciences Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Prothena Public Limited's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Prothena Public Limited's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Eli Lilly And Company | Reportable 100.00 % |
| Amgen Inc | Reportable 100.00 % |
| Vertex Pharmaceuticals Inc | Pharmaceuticals 100.00 % |
| Teva Pharmaceutical Industries Limited | United States 42.55 % |
| Biogen Inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Prothena Corporation Public Limited Company.
Prothena Public Limited's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Prothena Corporation Public Limited Company | 458 | 813,881 | -656,597 |
| Eli Lilly And Company | 1,261,320 | 1,729,240 | 551,594 |
| Beone Medicines Ltd | 628,233 | 510,686 | 54,642 |
| Abbvie Inc | 519,728 | 1,158,140 | 181,509 |
| Astrazeneca Plc | 295,827 | 706,847 | 123,141 |
| Amgen Inc | 253,085 | 2,930,385 | 672,538 |
| PEERS TOTAL | 3,690,476 | 1,219,054 | 215,911 |
Sign in to see all peers for Prothena Corporation Public Limited Company.
Prothena Public Limited's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Eli Lilly And Company | United States 62.04 % |
| Beone Medicines Ltd | United States 54.39 % |
| Vertex Pharmaceuticals Inc | United States 63.04 % |
| Bristol myers Squibb Company | United States 69.43 % |
| Teva Pharmaceutical Industries Limited | Europe 30.49 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Prothena Corporation Public Limited Company.
Prothena Public Limited's Position in Industry Market Structure
Market-capitalization share and concentration across all 495 companies in Prothena Public Limited's industry classification, broader than the peer set above. Market cap in millions of $.Prothena Public Limited ranks #197 of 495 companies by market capitalization in its industry, holding 0.01 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 885, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,232,412 | 20.92 % |
| 2 | Johnson and Johnson | 679,690 | 11.54 % |
| 3 | Beone Medicines Ltd | 623,340 | 10.58 % |
| 4 | Abbvie Inc | 514,617 | 8.74 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Astrazeneca Plc | 1,234 | 5.2% |
| 197 | Prothena Corporation Public Limited Company | 416 | 0.01 % |
Market cap and industry share for the rest of Prothena Public Limited's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-09.
Prothena Public Limited's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 192 | Puma Biotechnology Inc | 437 | 69.52 % |
| 193 | Aquestive Therapeutics Inc | 436 | -43.07 % |
| 194 | Kamada Ltd | 435 | 12.54 % |
| 195 | Canton Strategic Holdings Inc | 427 | -52.53 % |
| 196 | Arvinas Inc | 1,234 | 12.3% |
| 197 | Prothena Corporation Public Limited Company | 416 | -20.78 % |
| 198 | Oculis Holding Ag | 1,234 | 12.3% |
| 199 | Rezolute Inc | 1,234 | 12.3% |
| 200 | Indaptus Therapeutics Inc | 1,234 | 12.3% |
| 201 | Assembly Biosciences Inc | 1,234 | 12.3% |
| 202 | Altimmune inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Prothena Public Limited's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-09. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Prothena Public Limited's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (445 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 0.00 % | 37.84 % (avg) | -37.8 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | -64.38 % | -6.50 % (avg) | -57.9 pp |
| Capital Intensity (Capex / Revenue) | 1.21 % | 7.56 % (avg) | -6.4 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Prothena Public Limited's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (445 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.6x | - |
| EV / EBITDA | - | 15.5x | - |
| P/B | 1.8x | 4.3x | -2.5x |
| Return on Equity | -14.98 % | industry aggregate | -31.33 % |
| Return on Invested Capital | -9.00 % | -9.84 % (avg) | 0.84 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Prothena Public Limited's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | -96.53 % | -14.76 % | 4.79 % | 500.00 % | -73.13 % | 69.50 % | 47.92 % | -92.83 % |
| Operating Margin | -16,634.03 % | -10,527.89 % | -13,216.18 % | 35.88 % | -244.05 % | - | - | - |
| Return on Invested Capital | -17.89 % | -11.92 % | -19.89 % | 8.47 % | -12.71 % | -15.15 % | -14.27 % | -30.40 % |
| P/E | - | - | - | 39.3x | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Prothena Public Limited's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Prothena Public Limited falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.1% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Prothena Public Limited's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 885 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 1.21 % vs industry average 7.56 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Prothena Public Limited's dedicated Suppliers and Customers pages, not here.
Prothena Public Limited's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Prothena Public Limited falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Prothena Public Limited's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 31.3 points below the industry aggregate.
- Latest-quarter revenue run-rate is decelerating (-92.6% annualized vs trailing 12 months).
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
Opportunities
- A meaningful share of competitors (48.20 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Prothena Public Limited's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Prothena Corporation Public Limited Company | 9.20 | 9.43 | - |
| Eli Lilly And Company | 0.16 | 1.44 | 1.44 |
| Beone Medicines Ltd | 2.30 | 3.16 | 0.23 |
| Abbvie Inc | 0.19 | 0.79 | - |
| Astrazeneca Plc | 0.19 | 0.94 | 0.51 |
| Amgen Inc | 0.46 | 1.26 | 5.86 |
Sign in to see all peers for Prothena Corporation Public Limited Company.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Prothena Public Limited's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Prothena Corporation Public Limited Company | Q2 2026 | -77.1 % | - |
| Eli Lilly And Company | Q3 2026 | +38.6 % | +15.6 % |
| Beone Medicines Ltd | Q2 2026 | +29.7 % | +151.3 % |
| Abbvie Inc | Q3 2026 | +10.3 % | +2,143.6 % |
| Astrazeneca Plc | Q4 2025 | +8.6 % | +45.3 % |
| Amgen Inc | Q2 2026 | +9.5 % | +65.9 % |
| PEERS TOTAL | +13.8 % | +50.5 % |
Sign in to see all peers for Prothena Corporation Public Limited Company.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Prothena Public Limited's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Prothena Corporation Public Limited Company | Q2 2026 | - | +658.1 % |
| Eli Lilly And Company | Q3 2026 | +30.7 % | +52.2 % |
| Beone Medicines Ltd | Q2 2026 | +6.4 % | -57.0 % |
| Abbvie Inc | Q3 2026 | -19.2 % | -21.0 % |
| Astrazeneca Plc | Q4 2025 | +11.2 % | +46.0 % |
| Amgen Inc | Q2 2026 | -6.6 % | +39.0 % |
Sign in to see all peers for Prothena Corporation Public Limited Company.
Prothena Public Limited's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Prothena Corporation Public Limited Company | - | - | - |
| Eli Lilly And Company | 21.24% | 32.00% | 83.65% |
| Beone Medicines Ltd | 7.82% | 10.32% | 14.24% |
| Abbvie Inc | 7.48% | 12.87% | - |
| Astrazeneca Plc | 8.97% | 19.67% | 21.00% |
| Amgen Inc | 9.48% | 13.08% | 89.32% |
Sign in to see all peers for Prothena Corporation Public Limited Company.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Prothena Public Limited's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Prothena Corporation Public Limited Company | - | 8.39 |
| Eli Lilly And Company | 45.84 | 14.59 |
| Beone Medicines Ltd | 948.48 | 102.51 |
| Abbvie Inc | 50.48 | 7.87 |
| Astrazeneca Plc | 28.96 | 5.04 |
| Amgen Inc | 28.90 | 6.64 |
| PEERS AVERAGE | 44.98 | 7.96 |
Sign in to see all peers for Prothena Corporation Public Limited Company.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.